Huan Yuhang, Wei Jing, Zhou Jingjing, Liu Min, Yang Jian, Gao Youhe
Department of Biochemistry and Molecular Biology, Gene Engineering Drug and Biotechnology Beijing Key Laboratory, Beijing Normal University, Beijing, China.
The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
Front Psychiatry. 2021 Sep 30;12:700149. doi: 10.3389/fpsyt.2021.700149. eCollection 2021.
Major depressive disorder (MDD) is a common mental disorder that can cause substantial impairments in quality of life. Clinical treatment is usually built on a trial-and-error method, which lasts ~12 weeks to evaluate whether the treatment is efficient, thereby leading to some inefficient treatment measures. Therefore, we intended to identify early candidate urine biomarkers to predict efficient treatment response in MDD patients. In this study, urine samples were collected twice from 19 respondent and 10 non-respondent MDD patients receiving 0-, 2-, and 12-week treatments with escitalopram. Differential urinary proteins were subsequently analyzed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Our two pilot tests suggested that the urine proteome reflects changes associated with major depressive disorder at the early stage of treatment measures. On week 2, 20 differential proteins were identified in the response group compared with week 0, with 14 of these proteins being associated with the mechanisms of MDD. In the non-response group, 60 differential proteins were identified at week 2, with 28 of these proteins being associated with the mechanisms of MDD. In addition, differential urinary proteins at week 2 between the response and non-response groups can be clearly distinguished by using orthogonal projection on latent structure-discriminant analysis (OPLS-DA). Our small pilot tests indicated that the urine proteome can reflect early effects of escitalopram therapy between the response and non-response groups since at week 2, which may provide potential early candidate urine biomarkers to predict efficient treatment measures in MDD patients.
重度抑郁症（MDD）是一种常见的精神障碍，会严重损害生活质量。临床治疗通常基于试错法，这种方法需要持续约12周来评估治疗是否有效，从而导致一些无效的治疗措施。因此，我们旨在识别早期候选尿液生物标志物，以预测MDD患者的有效治疗反应。在本研究中，从19名有反应和10名无反应的MDD患者中收集尿液样本，这些患者接受了0周、2周和12周的艾司西酞普兰治疗。随后通过液相色谱-串联质谱联用（LC-MS/MS）分析差异尿蛋白。我们的两项初步试验表明，尿液蛋白质组反映了治疗措施早期与重度抑郁症相关的变化。在第2周时，与第0周相比，反应组中鉴定出20种差异蛋白，其中14种蛋白与MDD的机制相关。在无反应组中，第2周时鉴定出60种差异蛋白，其中28种蛋白与MDD的机制相关。此外，通过使用潜在结构判别分析的正交投影（OPLS-DA），可以清楚地区分反应组和无反应组在第2周时的差异尿蛋白。我们的小型初步试验表明，尿液蛋白质组可以反映第2周时艾司西酞普兰治疗在反应组和无反应组之间的早期效果，这可能为预测MDD患者有效治疗措施提供潜在的早期候选尿液生物标志物。
